Equities

Guardant Health Inc

Guardant Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.39
  • Today's Change0.31 / 1.24%
  • Shares traded2.00m
  • 1 Year change-7.97%
  • Beta1.1131
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,1691,011933
Total Receivables, Net899798
Total Inventory625231
Prepaid expenses283253
Other current assets, total------
Total current assets1,3471,1921,114
Property, plant & equipment, net303342314
Goodwill, net3.293.293.29
Intangibles, net8.981214
Long term investments--0698
Note receivable - long term------
Other long term assets1246161
Total assets1,7861,6102,204
LIABILITIES
Accounts payable526918
Accrued expenses13610784
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total181794
Total current liabilities206193195
Total long term debt1,1401,1371,135
Total debt1,1401,1371,135
Deferred income tax------
Minority interest----0
Other liabilities, total282219230
Total liabilities1,6281,5501,559
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital2,3041,7421,658
Retained earnings (accumulated deficit)(2142)(1662)(1008)
Treasury stock - common------
Unrealized gain (loss)(3.68)(20)(4.76)
Other equity, total------
Total equity15960645
Total liabilities & shareholders' equity1,7861,6102,204
Total common shares outstanding122103100
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.